Literature DB >> 11465078

Drug-metabolizing enzymes: mechanisms and functions.

S A Sheweita1.   

Abstract

Drug-metabolizing enzymes are called mixed-function oxidase or monooxygenase and containing many enzymes including cytochrome P450, cytochrome b5, and NADPH-cytochrome P450 reductase and other components. The hepatic cytochrome P450s (Cyp) are a multigene family of enzymes that play a critical role in the metabolism of many drugs and xenobiotics with each cytochrome isozyme responding differently to exogenous chemicals in terms of its induction and inhibition. For example, Cyp 1A1 is particularly active towards polycyclic aromatic hydrocarbons (PAHs), activating them into reactive intermediates those covalently bind to DNA, a key event in the initiation of carcinogenesis. Likewise, Cyp 1A2 activates a variety of bladder carcinogens, such as aromatic amines and amides. Also, some forms of cytochrome P450 isozymes such as Cyp 3A and 2E1 activate the naturally occurring carcinogens (e.g. aflatoxin B1) and N-nitrosamines respectively into highly mutagenic and carcinogenic agents. The carcinogenic potency of PAHs, and other carcinogens and the extent of binding of their ultimate metabolites to DNA and proteins are correlated with the induction of cytochrome P450 isozymes. Phase II drug-metabolizing enzymes such as glutathione S-transferase, aryl sulfatase and UDP-glucuronyl transferase inactivate chemical carcinogens into less toxic or inactive metabolites. Many drugs change the rate of activation or detoxification of carcinogens by changing the activities of phases I and II drug-metabolizing enzymes. The balance of detoxification and activation reactions depends on the chemical structure of the agents, and is subjected to many variables that are a function of this structure, or genetic background, sex, endocrine status, age, diet, and the presence of other chemicals. It is important to realize that the enzymes involved in carcinogen metabolism are also involved in the metabolism of a variety of substrates, and thus the introduction of specific xenobiotics may change the operating level and the existence of other chemicals. The mechanisms of modification of drug-metabolizing enzyme activities and their role in the activation and detoxification of xenobiotics and carcinogens have been discussed in the text.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11465078     DOI: 10.2174/1389200003339117

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  40 in total

1.  Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients.

Authors:  Tongmeng Yan; Linlin Lu; Cong Xie; Jiamei Chen; Xiaojuan Peng; Lijun Zhu; Ying Wang; Qiang Li; Jian Shi; Fuyuan Zhou; Ming Hu; Zhongqiu Liu
Journal:  Mol Cancer Ther       Date:  2015-10-29       Impact factor: 6.261

Review 2.  Sequencing XMET genes to promote genotype-guided risk assessment and precision medicine.

Authors:  Yaqiong Jin; Geng Chen; Wenming Xiao; Huixiao Hong; Joshua Xu; Yongli Guo; Wenzhong Xiao; Tieliu Shi; Leming Shi; Weida Tong; Baitang Ning
Journal:  Sci China Life Sci       Date:  2019-05-20       Impact factor: 6.038

3.  MicroRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation.

Authors:  Dongying Li; Bridgett Knox; Si Chen; Leihong Wu; William H Tolleson; Zhichao Liu; Dianke Yu; Lei Guo; Weida Tong; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2019-08-22       Impact factor: 5.858

4.  Contamination by metals and pharmaceuticals in northern Taihu Lake (China) and its relation to integrated biomarker response in fish.

Authors:  Guanghua Lu; Xiaofan Yang; Zhihua Li; Haizhou Zhao; Chao Wang
Journal:  Ecotoxicology       Date:  2012-10-04       Impact factor: 2.823

5.  Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma.

Authors:  I Bergheim; E Wolfgarten; E Bollschweiler; A-H Hölscher; C Bode; A Parlesak
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

6.  Hepatic ameliorative role of vitamin B17 against Ehrlich ascites carcinoma-induced liver toxicity.

Authors:  Ehab Tousson; Ezar Hafez; Maha Mohamed Abo Gazia; Siham Bayomi Salem; Thulfiqar Fawwaz Mutar
Journal:  Environ Sci Pollut Res Int       Date:  2020-01-08       Impact factor: 4.223

7.  Assessment of Lipid Peroxidation and Antioxidant Status in Vanillic Acid Treated 7,12-Dimethylbenz[a]anthracene Induced Hamster Buccal Pouch Carcinogenesis.

Authors:  Vinoth Anbalagan; Kowsalya Raju; Manoharan Shanmugam
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Studies into radiolytic decomposition of fluorine-18 labeled radiopharmaceuticals for positron emission tomography.

Authors:  Peter J H Scott; Brian G Hockley; Hank F Kung; Rajesh Manchanda; Wei Zhang; Michael R Kilbourn
Journal:  Appl Radiat Isot       Date:  2008-09-07       Impact factor: 1.513

9.  Effects of long-term tea polyphenols consumption on hepatic microsomal drug-metabolizing enzymes and liver function in Wistar rats.

Authors:  Tao-Tao Liu; Ning-Sheng Liang; Yan Li; Fan Yang; Yi Lu; Zi-Qing Meng; Li-Sheng Zhang
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

10.  Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women.

Authors:  Ping Huang; Bing Zhu; Lian-Sheng Wang; Dong-Sheng Ouyang; Song-Lin Huang; Xiao-Ping Chen; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.